These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 24418330)

  • 1. Frequent copy number variations of PI3K/AKT pathway and aberrant protein expressions of PI3K subunits are associated with inferior survival in diffuse large B cell lymphoma.
    Cui W; Cai Y; Wang W; Liu Z; Wei P; Bi R; Chen W; Sun M; Zhou X
    J Transl Med; 2014 Jan; 12():10. PubMed ID: 24418330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma.
    Go H; Jang JY; Kim PJ; Kim YG; Nam SJ; Paik JH; Kim TM; Heo DS; Kim CW; Jeon YK
    Oncotarget; 2015 Jun; 6(17):15035-49. PubMed ID: 25909227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome.
    Huang J; Zhang L; Greshock J; Colligon TA; Wang Y; Ward R; Katsaros D; Lassus H; Butzow R; Godwin AK; Testa JR; Nathanson KL; Gimotty PA; Coukos G; Weber BL; Degenhardt Y
    Genes Chromosomes Cancer; 2011 Aug; 50(8):606-18. PubMed ID: 21563232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of AKT phosphorylation and PTEN loss and their correlation with the resistance of rituximab in DLBCL.
    Ma Y; Zhang P; Gao Y; Fan H; Zhang M; Wu J
    Int J Clin Exp Pathol; 2015; 8(11):14875-84. PubMed ID: 26823817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab.
    Xu ZZ; Xia ZG; Wang AH; Wang WF; Liu ZY; Chen LY; Li JM
    Ann Hematol; 2013 Oct; 92(10):1351-8. PubMed ID: 23636313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutations of the PIK3CA gene in diffuse large B cell lymphoma.
    Baohua Y; Xiaoyan Z; Tiecheng Z; Tao Q; Daren S
    Diagn Mol Pathol; 2008 Sep; 17(3):159-65. PubMed ID: 18382359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma Cell-Free DNA Profiling of PTEN-PI3K-AKT Pathway Aberrations in Metastatic Castration-Resistant Prostate Cancer.
    Kwan EM; Dai C; Fettke H; Hauser C; Docanto MM; Bukczynska P; Ng N; Foroughi S; Graham LK; Mahon K; Tan W; Wang X; Zhao Z; Zheng T; Zhou K; Yu J; Du P; Horvath LG; Jia S; Kohli M; Azad AA
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34250422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival.
    Uddin S; Hussain AR; Siraj AK; Manogaran PS; Al-Jomah NA; Moorji A; Atizado V; Al-Dayel F; Belgaumi A; El-Solh H; Ezzat A; Bavi P; Al-Kuraya KS
    Blood; 2006 Dec; 108(13):4178-86. PubMed ID: 16946303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of B-cell receptor expression defines a subset of diffuse large B-cell lymphoma characterized by silent BCR/PI3K/AKT signaling and a germinal center phenotype displaying low-risk clinicopathologic features.
    Wang WG; Cui WL; Wang L; Zhu F; Wan XC; Ping B; Zhou XY; Li XQ
    Am J Surg Pathol; 2015 Jul; 39(7):902-11. PubMed ID: 25970684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fc receptor-like 1 (FCRL1) is a novel biomarker for prognosis and a possible therapeutic target in diffuse large B-cell lymphoma.
    Yousefi Z; Sharifzadeh S; Zare F; Eskandari N
    Mol Biol Rep; 2023 Feb; 50(2):1133-1145. PubMed ID: 36409389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TCL1 as a hub protein associated with the PI3K/AKT signaling pathway in diffuse large B-cell lymphoma based on proteomics methods.
    Gao HX; Li SJ; Niu J; Ma ZP; Nuerlan A; Xue J; Wang MB; Cui WL; Abulajiang G; Sang W; Zhang W; Li XX
    Pathol Res Pract; 2020 Feb; 216(2):152799. PubMed ID: 31932115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P110α-mediated constitutive PI3K signaling limits the efficacy of p110δ-selective inhibition in mantle cell lymphoma, particularly with multiple relapse.
    Iyengar S; Clear A; Bödör C; Maharaj L; Lee A; Calaminici M; Matthews J; Iqbal S; Auer R; Gribben J; Joel S
    Blood; 2013 Mar; 121(12):2274-84. PubMed ID: 23341541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sirt6 promotes tumorigenesis and drug resistance of diffuse large B-cell lymphoma by mediating PI3K/Akt signaling.
    Yang J; Li Y; Zhang Y; Fang X; Chen N; Zhou X; Wang X
    J Exp Clin Cancer Res; 2020 Jul; 39(1):142. PubMed ID: 32711549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma.
    Guillermet-Guibert J; Bjorklof K; Salpekar A; Gonella C; Ramadani F; Bilancio A; Meek S; Smith AJ; Okkenhaug K; Vanhaesebroeck B
    Proc Natl Acad Sci U S A; 2008 Jun; 105(24):8292-7. PubMed ID: 18544649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancer.
    Sukawa Y; Yamamoto H; Nosho K; Kunimoto H; Suzuki H; Adachi Y; Nakazawa M; Nobuoka T; Kawayama M; Mikami M; Matsuno T; Hasegawa T; Hirata K; Imai K; Shinomura Y
    World J Gastroenterol; 2012 Dec; 18(45):6577-86. PubMed ID: 23236232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PIK3CA copy number aberration and activation of the PI3K-AKT-mTOR pathway in varied disease states of penile cancer.
    Adimonye A; Stankiewicz E; La-Touche S; Kudahetti S; Trevisan G; Tinwell B; Corbishley C; Lu YJ; Watkin N; Berney D
    PLoS One; 2018; 13(6):e0198905. PubMed ID: 29902261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma.
    Smith PG; Wang F; Wilkinson KN; Savage KJ; Klein U; Neuberg DS; Bollag G; Shipp MA; Aguiar RC
    Blood; 2005 Jan; 105(1):308-16. PubMed ID: 15331441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PIK3CB/p110β is a selective survival factor for glioblastoma.
    Pridham KJ; Le L; Guo S; Varghese RT; Algino S; Liang Y; Fajardin R; Rodgers CM; Simonds GR; Kelly DF; Sheng Z
    Neuro Oncol; 2018 Mar; 20(4):494-505. PubMed ID: 29016844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PIK3CA mutation and CNV status and post-chemoradiotherapy survival in patients with cervical cancer.
    Martell K; McIntyre JB; Kornaga EN; Chan AMY; Phan T; Köbel M; Enwere EK; Dean ML; Ghatage P; Lees-Miller SP; Doll CM
    Gynecol Oncol; 2020 Sep; 158(3):776-784. PubMed ID: 32653099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leptin receptor expression and its association with PI3K/AKT signaling pathway in diffuse large B-cell lymphoma.
    Uddin S; Bu R; Ahmed M; Hussain AR; Ajarim D; Al-Dayel F; Bavi P; Al-kuraya KS
    Leuk Lymphoma; 2010 Jul; 51(7):1305-14. PubMed ID: 20443680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.